Treatment of mouse bearing human melanoma cancer cells (A2058) with hFc-angiostatin. (A) Ten tumor-bearing SCID mice in each group were subcutaneously treated with hFcAS, hFc (100 μg/mouse once every 6 days), or PBS. Treatment was stopped before the development of necrosis. Sites of injection were away from tumors. Tumor sizes and the ratio of treated/control (T/C) and P values are shown for the hFcAS-treated group. (B) Immunostaining shows that treated angiostatin (green) only bound in tumor masses but not in normal organs, such as liver, heart, and kidney. CD31 staining for vessels (red) and DAPI for nuclei (blue; original magnification ×20) is also presented. (C) ELISAs of circulating human IgG concentrations are shown 4 days after the last injection. (D) TUNEL assay shows more apoptosis cells in tumor area and no TUNEL-positive cells in normal organs after the treatment. Bar represents 20 μm.